|
Avemar research history1937: Professor Albert Szent-Györgyi won the Nobel Prize in Physiology and Medicine for his discoveries in connection with the biological combustion processes, with special reference
to vitamin C.
Avemar research history 1941: Huller and Stern analyzed the chemical changes during the fermentation of wheat germ with yeast.
Avemar research history 1960’s: Albert Szent-Györgyi presumes that the lack of ascorbic acid and methoxy-substituted benzoquinones is related to the development of malignancies. His idea was that these compounds also might have primary roles in maintaining immunity.
Avemar research history 1992:
Máté Hidvégi – based on the ideas of Szent-Györgyi – works on the production of a natural-based quinone-concentrate. Rita Tömösközi-Farkas, who works in the laboratory of Hermann Esterbauer in Graz., joins the research program.
Avemar research history 1995: Károly Lapis, Béla Szende and Erzsébet Rásó find that Hidvégi’s extract of wheat germ significantly inhibits, if combined with chemotherapeutic agents prevents malignant tumors from metastasizing. These results are based on research using several thousand animals.
Avemar research history 1996:
As a result of further animal studies they postulate that the extract’s immune-reconstructive properties are primarily responsible for these incredible effects. They also point out that this agent selectively inhibits adhesion, division of cancer cells and increases their apoptosis. The experiments of László Prónai in Japan show the antioxidant qualities of the extract. Avemar did not prove to be poisonous in toxicological investigations. The experiments are funded by private individuals: Mihály Kupa and Ákos Resetár, economists. |
Avemar research history 1997: Professor Máté Hidvégi, László Nagypál and Klára Dési elaborate the industrial manufacturing technology of the extract. The final steps are developed in Israel.
Avemar research history 1998: Avemar’s professional presentation in Tel Aviv and Budapest. OÉTI approves the distribution of Avemar as a dietary supplement.
Avemar research history 1999:
The teams of Éva Monostori and Erno Duda start to clear up the mechanism by which Avemar works.
Avemar research history 2000: Ferenc Jakab et al. find that Avemar in patients with colon and rectal cancer retards the progression of cancer growth including the development of metastases. Ottó Ribári et al. experience beneficial effects of the preparation in patients with head and neck cancer. Ádám Balogh et al. find that Avemar considerably reduces the side effects of chemotherapy. The latter is reaffirmed by experiments of Júlia Gidáli et al. Géza Bálint et al. show that the product is clinically efficient in rheumatoid arthritis. György Falkay et al. demonstrate the general anti-inflammatory effect of Avemar. Attila Zalatnai et al. prove the ability of the preparation to prevent cancer. Yehuda Shoenfeld et al. in Tel Aviv University show the effectiveness of the product in SLE. László Boros et al. at UCLA realize that Avemar inhibits the division of cancer cells by a mechanism independent of the immune system.
|
Avemar research history 2001: Anna Tompa et al. show that Avemar is able to improve the immune system also in patients not having cancer. Schoenfeld’s team realizes that Avemar inhibits autoimmune atherosclerosis. Lev Demidov et al. at Moscow Blokhin Oncology Institute find that Avemar inhibits the development of metastases in patients with melanoma. Ferenc Jakab, Ádám Balogh and Péter Sápy prove that Avemar not only holds up progression, but significantly prolongs survival in advanced colon and rectal cancer. Zoltán Ajkay et al. show that the preparation considerably improves quality of life of patients afflicted by advanced lung cancer. Éva Monostori, Erno Duda, Erika Kiss-Tóth and Steven Dower from the University of Sheffield publish Avemar’s hypothetical mechanism of action. Based on comparative laboratory studies of Avemar and anticancer drugs, Marta Cascante at Barcelona University and László Boros at UCLA presume that Avemar also might be of use for treating stage IV. cancer patients. By synthesis of the results András Telekes outlines Avemar’s complex mechanism of action.
Avemar research history 2002: Avemar is registered in Hungary as a “medical nutriment for cancer patients”.
Avemar research history 2003:
Avemar gets approved label with similar cancer claims in the Czech Republic and Bulgaria. At this time Avemar is available in 10 countries around the world. "A medical nutriment has supportive value in the treatment of colorectal cancer." - First time clinical data regarding a medical nutriment are published in the British Journal of Cancer. Since 2004, there have been 20 more studies completed in many different countries. They are now published in peer-reviewed medical journals.
|
|
